证券代码：603880 证券简称：南卫股份 公告编号：2025-024 江苏南方卫材医药股份有限公司 关于公司相关人员收到中国证券监督管理委员会 《行政处罚决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 江苏南方卫材医药股份有限公司（以下简称"公司"）控股股东及实际控制人 李平于2024年10月23日收到中国证券监督管理委员会（以下简称"中国证监会"） 下发的《立案告知书》（编号：证监立案字0102024025号），公司前任财务总监项 琴华于同日收到中国证监会下发的《立案告知书》（编号：证监立案字0102024026 号），因涉嫌内幕交易，根据《中华人民共和国证券法》《中华人民共和国行政处 罚法》等法律法规，中国证监会决定对李平和项琴华立案。具体内容详见公司于2024 年10月24日披露的《南卫股份关于控股股东及高级管理人员收到中国证券监督管理 委员会立案告知书的公告》（公告编号：2024-043）。 2025年8月7日，公司前任财务总监项琴华收到中国证券监督管理委员会江苏监 管局下发的《行政处罚事先告知 ...

公募基金方面，本期较上一季未再披露的公募基金共计2个，包括新华中小市值优选混合、西部利得量 化优选一年持有期混合A。 MACD金叉信号形成，这些股涨势不错！ 2025年10月31日，南卫股份（维权）(603880.SH)发布2025年第三季报。截至2025年10月30日，共有1个 机构投资者披露持有南卫股份A股股份，合计持股量达733.05万股，占南卫股份总股本的2.54%。其 中，机构投资者包括苏州蓝盈创业投资合伙企业(有限合伙)，机构投资者合计持股比例达2.54%。相较 于上一季度，机构持股比例合计下跌了0.02个百分点。 ...

Core Viewpoint - Nanwei Co., Ltd. is a well-known enterprise in the medical dressing industry in China, focusing on the research, production, and sales of medical dressing products, with its product quality and technology ranking among the top in the industry [1] Group 1: Business Performance - For Q3 2025, Nanwei's revenue was 447 million yuan, ranking 33rd out of 50 in the industry, significantly lower than the top competitor, Yingke Medical, which reported 7.425 billion yuan [2] - The main business revenue breakdown includes 121 million yuan from adhesive bandages, accounting for 39.59%, and 86.05 million yuan from protective products, accounting for 28.11% [2] - The net profit for the same period was -24.84 million yuan, ranking 47th out of 50, far below the industry average of 183 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Nanwei's debt-to-asset ratio was 73.87%, an increase from 63.01% in the previous year, significantly higher than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 10.68%, down from 12.41% in the previous year and well below the industry average of 48.78% [3] Group 3: Executive Compensation - The chairman and general manager, Li Ping, received a salary of 602,100 yuan in 2024, a slight increase from 600,800 yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 16.70% to 12,000, while the average number of circulating A-shares held per account increased by 20.05% to 24,000 [5]

江苏南方卫材医药股份有限公司 2025 年第三季度报告 证券代码：603880 证券简称：南卫股份 江苏南方卫材医药股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李平、主管会计工作负责人李平及会计机构负责人（会计主管人员）王亚华保证季度 报告中财务信息的真实、准确、完整。 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 141,229,954.25 | -7.81 ...

Core Viewpoint - Nanwei Co., Ltd. experienced a stock price decline of 2.14% on October 29, 2023, with a current price of 6.41 CNY per share, reflecting a total market capitalization of 1.853 billion CNY [1] Group 1: Stock Performance - Year-to-date, Nanwei's stock price has increased by 47.36%, while it has seen a decline of 0.77% over the last five trading days [1] - In the past 20 days, the stock price has risen by 9.01%, but it has decreased by 5.04% over the last 60 days [1] Group 2: Company Overview - Nanwei Co., Ltd. was established on July 4, 1990, and went public on August 7, 2017, focusing on the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [1] - The company's revenue composition includes: 39.59% from adhesive bandages, 28.11% from protective products, 22.54% from adhesive tapes and bandages, 5.01% from dressings, 2.63% from first aid kits, 1.71% from other products, and 0.40% from topical agents [1] Group 3: Financial Performance - For the first half of 2025, Nanwei reported a revenue of 306 million CNY, representing a year-on-year growth of 1.39%, while the net profit attributable to shareholders was -12.97 million CNY, a decrease of 1363.32% compared to the previous year [1] - As of June 30, 2025, the number of shareholders increased by 48.53% to 14,500, with an average of 19,986 circulating shares per person, down by 32.67% [1] Group 4: Dividend and Institutional Holdings - Since its A-share listing, Nanwei has distributed a total of 77.527 million CNY in dividends, with no dividends paid in the last three years [2] - As of June 30, 2025, the top ten circulating shareholders saw the exit of Huaxia CSI 500 Index Enhanced A (007994) from the list [2]

Group 1 - The core point of the article is that Nanwei Co., Ltd. announced that its controlling shareholder, Mr. Li Ping, has pledged part of his shares, specifically 3 million shares [2] Group 2 - The announcement was made on the evening of September 23 [2] - The pledge of shares indicates a potential change in the liquidity position of the controlling shareholder [2] - The company is subject to market scrutiny following this pledge, as it may affect investor confidence [2]

Group 1 - The core point of the article is that Jiangsu Nanfang Weicai Pharmaceutical Co., Ltd. announced significant share pledges by its controlling shareholder, Mr. Li Ping, which raises concerns about the company's financial stability and governance [1] Group 2 - As of the announcement date, Mr. Li Ping holds approximately 119 million shares, accounting for 41.12% of the company's total share capital [1] - Mr. Li Ping and his concerted actors, Mr. Li Yongping and Mr. Li Yongzhong, collectively hold about 137 million shares, representing 47.25% of the total share capital [1] - After the partial share pledge, Mr. Li Ping has pledged a total of 87.4 million shares, which is 73.54% of his total holdings and 30.24% of the company's total share capital [1] - Mr. Li Ping and his concerted actors have collectively pledged approximately 97.04 million shares, which is 71.06% of their total holdings and 33.57% of the company's total share capital [1]

一、上市公司股份质押 证券代码：603880 证券简称：南卫股份 公告编号：2025-023 江苏南方卫材医药股份有限公司关于 控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至本公告披露日，江苏南方卫材医药股份有限公司（以下简称"公司"） 控股股东李平先生持有公司股份 118,841,048 股，占公司总股本的 41.12%。公 司控股股东李平先生及一致行动人李永平先生、李永中先生合计持有公司股份 136,560,415 股，占公司总股本的 47.25%。本次部分股份质押后，李平先生累计 质押公司股份 87,400,000 股，占其持有公司股份总数的 73.54%，占公司总股本 的 30.24%，李平先生及其一致行动人李永平先生、李永中先生累计质押公司股 份97,039,338股，占其合计持有公司股份总数的71.06%，占公司总股本的33.57%。 公司于 2025 年 9 月 23 日接到公司控股股东李平先生通知，获悉其所持部分 公司股份办理质押业务，具体事项如下： 2. ...

Core Viewpoint - Nanjing South Medical Co., Ltd. (南卫股份) has experienced a stock price increase of 37.47% year-to-date, but has seen a decline of 5.23% in the last five trading days and 11.54% in the last twenty days, indicating volatility in its stock performance [2]. Company Overview - Nanjing South Medical Co., Ltd. was established on July 4, 1990, and listed on August 7, 2017. The company specializes in the research, production, and sales of transdermal products, medical adhesive tapes, bandages, sports protection products, first aid kits, and nursing products [2]. - The revenue composition of the company includes: 39.59% from adhesive bandages, 28.11% from protective products, 22.54% from adhesive tapes and bandages, 5.01% from dressings, 2.63% from first aid kits, 1.71% from other products, and 0.40% from topical agents [2]. Financial Performance - For the first half of 2025, Nanjing South Medical reported a revenue of 306 million yuan, representing a year-on-year growth of 1.39%. However, the net profit attributable to the parent company was a loss of 12.97 million yuan, a significant decrease of 1363.32% compared to the previous year [2]. - The company has distributed a total of 77.52 million yuan in dividends since its A-share listing, but has not issued any dividends in the last three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Nanjing South Medical was 14,500, an increase of 48.53% from the previous period. The average number of circulating shares per shareholder was 19,986, a decrease of 32.67% [2]. - Notably, the index-enhanced fund 华夏中证500指数增强A (007994) has exited the list of the top ten circulating shareholders [3].

证券代码：603880 证券简称：南卫股份 公告编号：2025-022 江苏南方卫材医药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 16 日（星期四）至 10 月 22 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@nanfangmedical.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 江苏南方卫材医药股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 23 日（星期四） 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本 ...